Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rechARge phase 3 trial of BMS-986365 versus investigator's choice in metastatic castration-resistant prostate cancer
2024-517422-25-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- May 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of BMS-986365 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Celgene Corporation. Primary endpoint: radiographic progression-free survival. Planned start May 2025; status: authorised.
02
Drugs
BMS-986365
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-517422-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517422-25-00.